Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicure (MCUJF) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Medicure (MCUJF) over the last 17 years, with Q3 2025 value amounting to -$922597.8.

  • Medicure's Income from Continuing Operations fell 28508.36% to -$922597.8 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year decrease of 73400.28%. This contributed to the annual value of $377252.5 for FY2024, which is 4110.17% down from last year.
  • As of Q3 2025, Medicure's Income from Continuing Operations stood at -$922597.8, which was down 28508.36% from -$483547.4 recorded in Q2 2025.
  • In the past 5 years, Medicure's Income from Continuing Operations registered a high of $4.0 million during Q4 2022, and its lowest value of -$1.5 million during Q4 2021.
  • Moreover, its 5-year median value for Income from Continuing Operations was $286614.2 (2023), whereas its average is $285274.6.
  • In the last 5 years, Medicure's Income from Continuing Operations surged by 328403.8% in 2021 and then plummeted by 123796.48% in 2025.
  • Medicure's Income from Continuing Operations (Quarter) stood at -$1.5 million in 2021, then soared by 370.66% to $4.0 million in 2022, then tumbled by 95.45% to $180695.7 in 2023, then soared by 119.08% to $395864.6 in 2024, then plummeted by 333.06% to -$922597.8 in 2025.
  • Its last three reported values are -$922597.8 in Q3 2025, -$483547.4 for Q2 2025, and -$430694.4 during Q1 2025.